Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 6, 2007, Pages 295-299

  Glaysher, Jennifer ^a   van Heyningen, Charles ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 37849052543     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070060701     Document Type: Article

References (20)

1. Sviridov D, Nestel P. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007;18:157-63.
2. Lan D, Silver D. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem 2005; 280:23390-6.
3. Nissen S, Nicholls S, Wolski K et al. Effect of a potent and selective PPAR-agonist in patients with atherogenic dyslipidaemia or hypercholesterolaemia. Two randomised controlled trials. JAMA 2007;297:1362-73.
4. Hiukka A, Leinonen E, Jauhainen M et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007;EPub ahead of print
5. Ribas V, Palomer X, Roglans N et al. Paradoxical exacerbation of combined hyperlipidaemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochimica et Biophysica Acta 2005; 1737:130-7
6. Gilde A, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. JACC 2006;48(suppl):A24-A32.
7. Tai E, Collins D, Robins S et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trials (VA-HIT). Atherosclerosis 2006;187:153-60.
8. Olukoga A. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2002;55:718.
9. Gutschi L, Malcolm J, Favreau C, Ooi T. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-6.
10. Collinson PO, Hjelm CJ, Canep-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996;33:159-61.
11. Oleesky D, Mir M. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 1997:34:573-4.
12. Chandler HA, Batchelor AJ. Ciprofibate and lipid profile. Lancet 1994;344:128-9.
13. McLeod AJ, Warren RJ, Armitage M. Ciprofibrate and lipid profile. Lancet 1994;344;955.
14. Capps NE. Lipid profiles on fibric-acid derivatives. Lancet 1994;344;684-5.
15. Shetty C, Balasubramani M, Capps N et al. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet med 2007;24:94-7.
16. Murali M, Kratz A, Finberg K. Case 40-2006: A 64 year old man with anaemia and a low level of HDL-cholesterol. N Engl J Med 2006; 355:2772-9.
17. Normen L, Frohlich J, Montaner J et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-2.
18. McLeod AJ, Warren RJ, Armitage M. Abnormal lipid profiles on fibrate derivatives. Lancet 1996;347:261.
19. Crook MA, Lynas J, Wray R. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2000;53:796-7.
20. Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR-α/ γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 2006;71:52-8.